| Literature DB >> 34371718 |
Laura E McCoubrey1, Moe Elbadawi1, Mine Orlu1, Simon Gaisford1, Abdul W Basit1.
Abstract
The human gut microbiome, composed of trillions of microorganisms, plays an essential role in human health. Many factors shape gut microbiome composition over the life span, including changes to diet, lifestyle, and medication use. Though not routinely tested during drug development, drugs can exert profound effects on the gut microbiome, potentially altering its functions and promoting disease. This study develops a machine learning (ML) model to predict whether drugs will impair the growth of 40 gut bacterial strains. Trained on over 18,600 drug-bacteria interactions, 13 distinct ML models are built and compared, including tree-based, ensemble, and artificial neural network techniques. Following hyperparameter tuning and multi-metric evaluation, a lead ML model is selected: a tuned extra trees algorithm with performances of AUROC: 0.857 (±0.014), recall: 0.587 (±0.063), precision: 0.800 (±0.053), and f1: 0.666 (±0.042). This model can be used by the pharmaceutical industry during drug development and could even be adapted for use in clinical settings.Entities:
Keywords: artificial intelligence; computational prediction and screening; digital health; drug discovery and development; in silico; metabolism of biopharmaceuticals and medicines; microbiota; toxicology; xenobiotics
Year: 2021 PMID: 34371718 DOI: 10.3390/pharmaceutics13071026
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.321